Bionano Genomics Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss
September 21 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
publication of a study utilizing OGM to detect cryptic balanced
chromosomal rearrangements (BCRs) found in subjects who experienced
recurrent pregnancy loss (RPL). Compared to traditional cytogenetic
methods, OGM successfully identified cryptic reciprocal
translocation in all samples, improving the success rate for
finding pathogenic variants of cryptic BCRs and streamlining the
process of detection.
Researchers analyzed samples from 11 couples who dealt with RPL,
had a history of an affected child or fetus with chromosome loss or
gain, or had a history of infertility to determine OGM’s utility
for detection of cryptic BCRs, which can significantly increase the
risk of delivering abnormal offspring with congenital malformations
or miscarriage for carrier couples. OGM showed 100% concordance
with the results from fluorescence in situ hybridization (FISH) and
sequencing analyses and revealed additional complex rearrangement
events such as inverted aberrations, further refining potential
genetic interpretation. The study authors highlighted challenges
associated with using traditional methods and cited OGM’s rapid and
robust detection of cryptic BCRs with a high resolution as evidence
of its potential application as a first-line method in routine
clinical genetic testing.
Erik Holmlin, PhD, president and chief executive officer of
Bionano commented, “This study shows support for OGM in an area
that we believe may prove to be very helpful to people struggling
with infertility and pregnancy loss. We are gratified to see the
researchers’ recommendation that OGM be adopted as a primary method
to replace traditional methods, some of which have been around for
50 years.”
This publication can be found here:
https://jmg.bmj.com/content/early/2022/06/15/jmedgenet-2022-108553
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “can,” “believe” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances) convey uncertainty of future events or
outcomes and are intended to identify these forward-looking
statements. Forward-looking statements include statements regarding
our intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the ability and
utility of OGM to detect cryptic BCRs. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes
in the competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
future study results to support those demonstrated in the paper
referenced in this press release; failure OGM to detect cryptic
BCRs; changes in our strategic and commercial plans; our ability to
obtain sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024